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Abstract 
Objectives. The enlargement of the left atrium has been identified as a marker of chronically increased left ventricular 
filling pressure and left ventricular diastolic dysfunction. This study aims to evaluate the association of indexed left 
atrial diameter with stroke, cardiovascular mortality, the combined event, and all-cause mortality in patients who 
underwent aortic valve surgery. 
Methods. Indexed left atrial diameter was measured in 2011 adult patients (mean age, 70.9 ± 10.8 years; 58.7% were 
men) who underwent aortic valve surgery between January 2008 and March 2016. 
Results. On the basis of the criteria of the American Society of Echocardiography, indexed left atrial diameter was 
normal in 64% of patients, mildly enlarged in 12.4% of patients, moderately enlarged in 9.2% of patients, and 
severely enlarged in 14.3% of patients. Over a mean follow-up period of 3.2 ± 2.1 years, there were 334 deaths and 
97 strokes. Cardiovascular mortality survival at 5 years among patients with normal, mild, moderate, and severe left 
atrial enlargement was 91.6%, 86.8%, 77.9%, and 77.4%, respectively (P < .001). After covariable adjustment, Cox 
regression analysis showed indexed left atrial diameter as an independent predictor of all-cause mortality (hazard 
ratio per 1-cm/m2 increment, 1.545; 95% confidence interval, 1.252-1.906, P < .001), cardiovascular death (hazard 
ratio per 1-cm/m2 increment, 1.971; 95% confidence interval, 1.541-2.520; P < .001), and the combined event (hazard 
ratio per 1-cm/m2 increment, 1.673; 95% confidence interval, 1.321-2.119; P < .001). 
Conclusions. Indexed left atrial diameter is a strong predictor of long-term outcomes in patients with aortic valve 
diseases who undergo surgery. 
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Different left atrial (LA) measurements have been proposed as predictors of long-term outcome in the 
general population,
1,2
 but also in specific subgroups of patients, such as those with left ventricular 
dysfunction,
3
 myocardial infaction,
4
 or hyperthophic cardiomyodiopathy.
5
 However, little information is 
available in the literature on the relationship between indexed LA size and outcome among patients who 
are referred for aortic valve surgery (AVS). 
 
The enlargement of the left atrium has been identified as a marker of chronically increased left 
ventricle (LV) filling pressure and LV diastolic dysfunction.
6
 Increased nonindexed LA diameter has 
been described as a marker of diastolic dysfunction among patients with asymptomatic aortic stenosis,
7
 as 
well as a factor of poor outcome in patients undergoing AVS.
8
 However, little is known about the long-
term prognostic value of indexed LA diameter in patients with chronic LV pressure or volume overload 
due to an aortic valve condition. 
 
The aim of this study is to determine the association between indexed LA diameter with all-cause 
mortality and cardiovascular mortality, as well as with stroke and the combined event cardiovascular 
death or stroke in a large cohort of patients with aortic valve diseases who underwent AVS. 
MATERIALS AND METHODS 
Between January 2008 and March 2016, 2460 adult patients (age >18 years) underwent AVS at 
Complejo Hospitalario Universitario de A Coruña. For each patient, the first comprehensive transthoracic 
echocardiogram was selected. We excluded 400 patients for whom the LA indexed size was not reported 
and 49 patients for whom no follow-up data were available. Thus, 2011 patients were finally included. 
The study was approved by the local research ethics committee (Comité Etico de Investigación Clínica de 
Galicia) (Study Identification Number 2016/259).  
Clinical Data  
Demographic, clinical, and echocardiographic data were entered in our surgical database. The study 
was completed using linked clinical and administrative databases, as well as electronic medical records 
through the Department of Information Technology of Complejo Hospitalario Universitario de A Coruña. 
Data sources were linked using unique identifiers.  
 
A history of atrial fibrillation was defined as atrial fibrillation recorded at the time of the admission 
for AVS or any previously known episode of atrial fibrillation. Creatinine clearance was calculated using 
the Cockcroft–Gault formula. Extracardiac arteriopathy was defined as 1 or more of the following factors: 
claudication, carotid occlusion or more than 50% stenosis, amputation for arterial disease, and previous or 
planned intervention on the abdominal aorta, limb arteries, or carotid arteries. Chronic lung disease was 
defined as long-term use of bronchodilators or steroids for lung disease. Active endocarditis was 
considered when the patient was still receiving antibiotic treatment for endocarditis at the time of surgery.  
 
Postoperative standard anticoagulation with vitamin K antagonists (VKAs) and heparin was initiated 
after surgery in all patients receiving a mechanical prosthesis, patients with chronic or new-onset atrial 
fibrillation or atrial flutter, or patients with other less common indications to the appropriate target 
international normalized ratio, as recommended by current practice guidelines.  
  
Echocardiographic Data 
Echocardiograms were performed in the left lateral decubitus position using standard imaging planes, 
according to the recommendations of the American Society of Echocardiography.
9
 LA diameter was 
measured using M-mode or 2-dimensional echocardiography, from the posterior aortic wall to the 
posterior LA wall, in the parasternal long-axis view at the end-ventricular systole (ie, just before the 
mitral valve opening), as we have previously reported.
10
  
 
LA size was indexed by dividing by body surface area (BSA) according to the recommendations of 
the American Society of Echocardiography.9 Although there are sex differences in LA size, these are 
nearly completely accounted for by variation in body size.
9,11,12
  
 
LA enlargement was defined as an indexed LA diameter of 2.3 cm/m
2
 or greater; an indexed LA 
diameter below this value defined normal LA size. LA enlargement was further classified as mild 
(indexed LA diameter, 2.4-2.6 cm/m
2
), moderate (2.7-2.9 cm/m
2
), or severe (≥3 cm/m2) in accordance 
with the recommendations of the American Society of Echocardiography.
9
  
 
Left ventricular ejection fraction (LVEF) was estimated using the Teichholz formula or Simpson’s 
rule. Normal LV function was defined as LVEF 55% or greater.
9
 Left ventricular systolic dysfunction was 
classified as mild (LVEF 45%-54%), moderate (30%-45%), or severe (<30%) in accordance with the 
recommendations of the American Society of Echocardiography.
9
  
 
Pulmonary hypertension was classified according to the systolic pulmonary artery pressure classified 
as moderate (31-55 mm Hg) and severe (>55 mm Hg). Significant mitral valve disease was defined as 
more than mild mitral regurgitation or significant mitral valve stenosis.  
Follow-up and Outcome Measures  
Follow-up data were retrieved from healthcare databases, electronic medical records, and death 
certificates. The outcomes were stroke, cardiovascular mortality, the combined event, and all-cause 
mortality.  
 
Cardiovascular death was defined as death due to acute myocardial infarction, sudden cardiac death, 
heart failure, stroke, cardiovascular procedure, cardiovascular hemorrhage, and other cardiovascular 
causes (ie, nonstroke intracranial hemorrhage, nonprocedural or nontraumatic vascular rupture, or 
pulmonary hemorrhage from a pulmonary embolism) as recommended by the American College of 
Cardiology.
13
 Ischemic stroke was defined as codes 433.x1, 434.x1, and 436 of the International 
Classification of Diseases, Ninth Revision.  
Statistical Analysis  
The quantitative variables are expressed as mean and standard deviation or median and rank, when 
appropriate; the qualitative variables are expressed as an absolute value (n) and the percentage. For 
bivariate analysis, proportions were compared with contingency tables by means of the chisquare test. 
Student t test or Wilcoxon rank-sum test was used to compare means. One-way analysis of variance was 
used to determine potential differences in several quantitative variables among the different LA sizes.  
 
Survival was determined with Kaplan–Meier methodology. Differences in the probability of survival 
between groups were analyzed with the log-rank (Mantel–Cox) test. Binary logistic regression analysis 
was performed to study the potential impact of indexed LA diameter on operative mortality.  
  
Cox proportional hazards regression models were used to assess the associations between indexed LA 
diameter and outcomes. Adjusted hazard ratio (HR), 95% confidence intervals (CIs), and P values were 
derived. The assumption of proportionality of hazards was verified using log-minus-log survival plots. 
Separate analyses were performed using indexed LA diameter as a continuous variable or categorized 
according to the severity criteria of the American Society of Echocardiography.
9
 The linearity assumption 
of the continuous variables in the model was evaluated by applying restricted cubic spline transformations 
to the continuous measures using 3 degrees of freedom.  
 
Fine-Gray proportional hazard regression for competing events (death) was used to assess the 
associations between indexed LA diameter and stroke, also adjusting for covariates. Multivariate Cox 
proportional hazards regression models were adjusted for the following covariables: age, sex, BSA, 
creatinine clearance, diabetes mellitus, arterial hypertension, dyslipidemia, previous stroke or transient 
ischemic attack, history of atrial fibrillation or atrial flutter, history of coronary artery disease, severity of 
left ventricular dysfunction, severity of pulmonary hypertension, type of aortic valve disease, chronic 
lung disease, extracardiac arteriopathy, active endocarditis, history of cardiac surgery, type of AVS, 
significant mitral valve disease, concomitant mitral valve intervention, concomitant tricuspid valve 
intervention, concomitant surgery on thoracic aorta, and concomitant coronary surgery.  
 
The study adheres to the STrengthening the Reporting of OBservational studies in Epidemiology 
initiative.
14
 The SPSS statistical program for Apple Macintosh version 22.0 (IBM Corporation, Armonk, 
NY) and R Statistical Software version 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria) 
were used to perform data analysis.    
RESULTS 
Clinical, Surgical, and Echocardiographic Characteristics 
The mean age of patients was 70.9 ± 10.8 years, and 1180 of them (58.7%) were men. The 
demographic and clinical characteristics are summarized in Table 1. The mean indexed LA diameter was 
2.4 ± 0.5 cm/m
2
. According to the criteria of the American Society of Echocardiography, indexed LA 
diameter was normal in 1287 patients (64%), mildly enlarged in 249 patients (12.4%), moderately 
enlarged in 185 patients (9.2%), and severely enlarged in 290 patients (14.4%).  
  
TABLE 1. Demographics, clinical risk factors, and surgical data of both groups 
Characteristic 
All patients 
(n = 2011) 
Normal left atrium 
(n = 1287) 
Enlarged left atrium 
(n = 724) 
P value 
     
Sex (male) 1180 (58.7%) 357 (49.4%) 366 (50.6%) <.001 
Age, y, mean (SD) 70.9 ± 10.8 69.2 ± 11.7 73.9 ± 8.1 <.001 
BMI, mean (SD) 28.7 ± 4.4 29.3 ± 4.4 27.5 ± 3.9 <.001 
BSA, m2, mean (SD) 1.8 ± 0.2 1.9 ± 0.2 1.7 ± 0.2 <.001 
Preoperative anticoagulation with VKAs 236 (11.7%) 80 (6.2%) 156 (21.6%) <.001 
Arterial hypertension 1367 (68%) 851 (66.1%) 516 (71.4%) .015 
Dyslipidemia 1101 (54.7%) 715 (55.5%) 386 (53.4%) .359 
Diabetes mellitus 496 (24.7%) 308 (23.9%) 188 (26%) .297 
Creatinine clearance, mL/min, mean (SD) 64.1 ± 27.4 64.2 ± 26.8 64.1 ± 28.4 .923 
Chronic lung disease 174 (8.7%) 116 (9%) 58 (8%) .451 
Extracardiac arteriopathy 127 (6.3%) 81 (6.3%) 46 (6.4%) .948 
History of atrial fibrillation 236 (11.7%) 80 (6.2%) 156 (21.6%) <.001 
History of stroke or TIA 90 (4.5%) 55 (4.2%) 35 (4.8%) .595 
History of cardiac surgery 181 (9%) 101 (7.8%) 80 (11.1%) .015 
Coronary artery disease 445 (22.1%) 267 (20.7%) 158 (21.8%) .588 
Active endocarditis 59 (2.9%) 40 (3.1%) 19 (2.6%) .542 
Predominant aortic valve stenosis 1639 (81.5%) 951 (79.3%) 579 (85.4%) .001 
Predominant aortic valve regurgitation 372 (18.5%) 249 (20.8%) 99 (14.6%)  
Moderate or severe mitral valve disease 444 (22.1%) 200 (15.5%) 244 (33.7%) <.001 
LV dysfunction     
Normal LVEF (>55%) 1626 (80.9%) 1069 (83%) 557 (77%) .003 
Mild LV dysfunction (45%-54%) 315 (15.7%) 182 (14.1%) 133 (18.4%)  
Moderate LV dysfunction (30%-45%) 61 (3%) 30 (2.3%) 31 (4.3%)  
Severe LV dysfunction (<30%) 9 (0.4%) 7 (0.5%) 2 (0.3%)  
Pulmonary hypertension     
Normal PAP 1519 (75.5%) 1061 (82.3%) 458 (63.4%)  
Moderate (31-55 mm Hg) 359 (17.9%) 189 (14.7%) 170 (23.5%) <.001 
Severe (>55 mm Hg) 133 (6.6%) 38 (3%) 95 (13.1%)  
Logistic euroSCORE I, mean (SD) 8.4 ± 7.4 7.8 ± 7.4 9.4 ± 7.3 <.001 
Logistic euroSCORE II, mean (SD) 4.3 ± 4.5 3.7 ± 4.3 5.3 ± 4.8 <.001 
Type of AVS     
Valve repair 53 (2.6%) 52 (4%) 1 (0.1%)  
Biological 1481 (73.6%) 902 (70%) 579 (80.1%) <.001 
Mechanical 477 (23.7%) 334 (25.9%) 143 (19.8%)  
Concomitant procedure 852 (42.4%) 533 (41.4%) 319 (44.1%) .24 
Concomitant mitral valve surgery 191 (9.5%) 60 (4.7%) 131 (18.1%) <.001 
Concomitant CABG 385 (19.1%) 242 (18.8%) 143 (19.8%) .588 
Concomitant surgery on thoracic aorta 305 (15.2%) 193 (15%) 112 (15.5%) .761 
     
 
SD, Standard deviation; BMI, body mass index; BSA, body surface area; VKA, vitamin K antagonist; TIA, transient ischemic 
attack; LV, left ventricle; LVEF, left ventricle ejection fraction; PAP, pulmonary artery pressure; euroSCORE, European System for 
Cardiac Operative Risk Evaluation; AVS, aortic valve surgery; CABG, coronary artery bypass grafting. 
Patients with LA enlargement were significantly older, more frequently female with increased mean 
body mass index and BSA, and a higher rate of arterial hypertension and history of atrial fibrillation 
(Table 1). LA enlargement was associated with a higher rate of preoperative LV dysfunction (23% vs 
17%, P = .003) and moderate to severe pulmonary hypertension (36.6% vs 17.7%, P<.001), as well as a 
higher rate of significant mitral valve disease and need for a mitral valve procedure (Table 1). Of note, an 
enlarged left atrium was significantly more prevalent in patients with aortic valve stenosis (579 patients, 
37.8%) than in patients with aortic valve regurgitation (99 patients, 28.4%) (P = .001).  
 
Mean indexed LA diameter was significantly higher in the group of patients with atrial fibrillation 
(2.8 ± 0.5 cm/m
2
 vs 2.4 ± 0.4 cm/m
2
, P<.001). Standard anticoagulation with VKAs at the time of surgery 
was significantly more frequent in patients with an enlarged LA (n = 156, 21.6%) than in patients with a 
normal LA (n = 80, 6.2%) (Table 1) (P<.001). The indication for preoperative VKAs was atrial 
fibrillation in all these patients. Operative data are shown in Table 1.   
The mean European System for Cardiac Operative Risk Evaluation (euroSCORE) I and II were 8.4% 
± 7.4% and 4.3% ± 4.6%, respectively. Patients with LA enlargement presented a significantly higher 
euroSCORE I and II (Table 1).  
 
A total of 181 patients (9%) had undergone a previous cardiac surgery. A history of cardiac surgery 
was more frequent among patients with LA enlargement (11.1% vs 7.8%, P = .015). An additional 
procedure at the time of the AVS was accomplished in 768 patients (n = 37.5%). The associated 
procedures are summarized in Table 1. Cardiopulmonary bypass and aortic crossclamping times were 
98.8 ± 57.9 minutes and 76.3 ± 33.7 minutes, respectively.  
 
The median intensive care unit stay was 2 days (range, 1-92 days), and the median in-hospital stay 
was 7 days (range, 3-152 days). Overall in-hospital mortality was 5.5% (111 patients). Overall in-hospital 
mortality for isolated AVS was 4.5% (52 patients) and reached 6.9% (59 patients) in combined AVS. 
There were no statistically significant differences in overall in-hospital mortality between the enlarged 
LA and normal LA groups (6.6% vs 4.9%, P = .1), in isolated AVS in-hospital mortality (4.7% vs 4.4%, 
P = .76), and in combined AVS in-hospital mortality (9.1% vs 5.6%, P = .07). Indexed LA diameter also 
was excluded as an independent risk factor for in-hospital mortality in a binary logistic regression 
analysis (odds ratio, 1.061; 95% CI, 0686-1.642; P = .789) (Table E1).  
Left Atrial Size and Outcomes  
Follow-up consisted of 5942.4 patient-years, and the mean follow-up was 3.2 ± 2.1 years. After 
hospital discharge, there were 334 deaths and 97 strokes during follow-up.  
 
Causes of death are summarized in Table 2. After hospital discharge, the most common cause of late 
death was cardiac disease (106 patients, 23.8%) followed by infectious disease (80 patients, 18%) and 
cancer (33 patients, 7.4%) (Table 2). Cardiac cause of death was significantly more frequent among 
patients with LA enlargement (87 deaths, 39% vs 19 deaths, 8.6%, P <.001). When considering inside 
cardiovascular mortality all the other causes recommended by the American College of Cardiology, 
cardiovascular deaths accounted for 55.9% of overall late deaths (n = 249). Cardiovascular mortality also 
remained significantly more frequent in the group with an enlarged LA (153 deaths, 68.6% vs 96 deaths, 
43.2%, P<.001). In 43 patients (9.7%) of the whole series, the cause of late death could not be 
determined. The 65.6% of patients with an unknown cause of death were aged more than 75 years.  
  
TABLE 2. Causes of death (n = 445) during the follow-up period including in-hospital mortality (n = 111 patients) 
Cause of death 
All patients 
(n = 445, 22.1%) 
Normal left atrium 
(n = 222, 17.2%) 
Enlarged left atrium 
(n = 223, 30.8%) 
P value 
     
30-d operative mortality  110 (24.7) 62 (27.9) 48 (21.7) .102 
In-hospital  111 (25) 63 (28.4) 48 (21.5) .094 
Short-term mortality causes     
Infectious  80 (18) 56 (25.2) 24 (10.8) <.001 
Cardiac  106 (23.8) 19 (8.5) 87 (39) <.001 
Stroke  26 (5.8) 10 (4.5) 16 (7.3) .229 
Trauma  8 (1.8) 5 (2.3) 3 (1.3) .471 
Gastrointestinal (noncancer)  7 (1.6) 1 (0.5) 6 (2.7) .057 
Vascular  6 (1.3) 2 (0.9) 4 (1.8) .414 
Unknown  43 (9.7) 30 (13.5) 13 (5.8) .006 
Long-term mortality causes     
Cancer disease  33 (7.4) 20 (9) 13 (5.8) .2 
Respiratory (noninfectious)  13 (2.9) 10 (4.5) 3 (1.3) .047 
Renal  12 (2.7) 6 (2.7) 6 (2.7) .993 
     
 
Percentages represent the proportion of each cause of death over overall deaths for each group (all patients; normal left atrium and 
enlarged left atrium). 
All-cause cumulative survival at 1 and 5 years was 94.6% and 91.6% among patients with normal LA 
size, 90% and 65.9% among patients with mild LA enlargement, 87.7% and 59.9% among patients with 
moderate LA enlargement, and 83.5% and 60.7% among patients with severe LA enlargement, 
respectively (P<.001) (Figure 1, A; Table E2).  
 
Cardiovascular cumulative survival at 1 and 5 years was 99.7% and 97.6% among patients with 
normal LA size, 96% and 86.8% among patients with mild LA enlargement, 95.9% and 77.9% among 
patients with moderate LA enlargement, and 96.1% and 77.4% among patients with severe LA 
enlargement, respectively (P<.001) (Figure 1, B; Table E2).  
 
In bivariate analysis, indexed LA diameter was significantly associated with all-cause mortality during 
follow-up (HR per 1-cm/m
2
 increment, 2.251; 95% CI, 1.892-2.677; P < .001). After covariable 
adjustment, multivariate Cox regression analysis showed indexed LA diameter as an independent 
predictor of all-cause mortality (adjusted HR per 1-cm/m
2
 increment, 1.545; 95% CI, 1.252-1.906; 
P<.001) (Table E3).  
 
Likewise, bivariate analysis suggested that indexed LA diameter was significantly associated with 
cardiovascular mortality during follow-up (HR per 1-cm/m
2
 increment, 1.871; 95% CI, 1.506-2.326; 
P<.001). After covariable adjustment, multivariate Cox regression analysis confirmed indexed LA 
diameter as an independent predictor of cardiovascular death (adjusted HR per 1-cm/m
2
 increment, 1.971; 
95% CI, 1.541-2.520; P<.001) (Table E4).  
 
There were 97 ischemic stroke events (4.8%) during the follow-up period. Freedom from stroke 
survival at 1 and 5 years was 98.5% and 94% among patients with normal LA size, 98.2% and 90.9% 
among patients with mild LA enlargement, 98.2% and 91.4% among patients with moderate LA 
enlargement, and 96.4% and 91.3% among patients with severe LA enlargement, respectively (P = .226) 
(Figure 2, A).  
 
In bivariate analysis, indexed LA diameter was significantly associated with the risk of stroke during 
follow-up (HR per 1-cm/m
2
 increment, 1.507; 95% CI, 1.072-2.119; P = .018). However, competing risks 
regression could not confirm that indexed LA diameter was associated with a higher risk of stroke (HR 
per 1-cm increment, 1.237; 95% CI, 0.724-2.114; P = .68) (Table E5).  
  
During the follow-up period, 313 patients (15.6%) had a stroke or a cardiovascular death, among 
whom 31 (1.5%) presented both events. Freedom from the combined event at 1 and 5 years was 93.3% 
and 87.2% among patients with normal indexed LA size, 89.3% and 74.5% among patients with mild LA 
enlargement, 89.9% and 68% among patients with moderate LA enlargement, and 84.2% and 64.5% 
among patients with severe LA enlargement, respectively (P<.001) (Figure 2, B). 
 
In bivariate analysis, indexed LA diameter was significantly associated with the risk of a combined 
event during follow-up (HR per 1-cm increment, 1.989; 95% CI, 1.685-2.347; P<.001). After covariable 
adjustment, multivariate Cox regression demonstrated indexed LA diameter as an independent risk factor 
for the combined event (HR per 1-cm/m
2
 increment, 1.673; 95% CI, 1.321-2.119; P<.001) (Table E6). 
 
Finally, a separate analysis was performed in patients according to the type of aortic valve lesion. 
Figure 3 depicts the cardiovascular cumulative survival in patients with aortic valve stenosis (Figure 3, A) 
and in patients with aortic valve regurgitation (Figure 3, B). In both subgroups, cardiovascular cumulative 
survival at 1 and 5 years was worse among patients with an enlarged LA. Indexed LA diameter was 
confirmed in an adjusted multivariate Cox regression analysis (Tables E7 and E8) as an independent 
predictor of cardiovascular death in patients with aortic valve stenosis (adjusted HR per 1-cm/m
2
 
increment, 1.947; 95% CI, 1.454-2.607; P<.001) or regurgitation (adjusted HR per 1-cm/m
2
 increment, 
1.925; 95% CI, 1.076-3.444; P = .027). 
  
 
 
 
FIGURE 1. A, Kaplan–Meier survival curves for all-cause mortality stratified according to indexed LA diameter (P<.001). B, 
Kaplan–Meier curves for cardiovascular survival stratified according to indexed LA diameter (P<.001). Normal indexed LA 
diameter less than 2.4 cm/m2; mild enlargement: 2.4 to 2.6 cm/m2; moderate enlargement: 2.7 to 2.9 cm/m2; severe enlargement: 3 
cm/m2 or more, in accordance with the recommendations of the American Society of Echocardiography.7 Table E2 reports Kaplan–
Meier survival at 1, 3, 5, and 7 years for each panel of each figure, including 95%confidence limits. 
 
  
 
 
 
FIGURE 2. A, Survival free of stroke stratified according to indexed LA diameter (P = .226). B, Survival free of the combined 
event, cardiovascular death or stroke, stratified according to indexed LA diameter (P<.001). Normal indexed LA diameter less than 
2.4 cm/m2; mild enlargement: 2.4 to 2.6 cm/m2; moderate enlargement: 2.7 to 2.9 cm/m2; severe enlargement: 3 cm/m2 or more in 
accordance with the recommendations of the American Society of Echocardiography.7 Table E2 reports Kaplan–Meier survival at 1, 
3, 5, and 7 years for each panel of each figure, including 95% confidence limits. 
  
 
 
 
FIGURE 3. A, Kaplan–Meier curves for cardiovascular survival in patients with aortic valve stenosis (n = 1639) stratified 
according to indexed LA diameter (P<.001). B, Kaplan–Meier curves for cardiovascular survival in patients with aortic valve 
regurgitation (n = 372) stratified according to indexed LA diameter (P<.001). Normal indexed LA diameter less than 2.4 cm/m2; 
mild enlargement: 2.4 to 2.6 cm/m2; moderate enlargement: 2.7 to 2.9 cm/m2; severe enlargement: 3 cm/m2 or more in accordance 
with the recommendations of the American Society of Echocardiography.7 Table E2 reports Kaplan–Meier survival at 1, 3, 5, and 7 
years for each panel of each figure, including 95% confidence limits. 
  
DISCUSSION 
Our study demonstrates that indexed LA measurement is a strong predictor of long-term outcomes in 
patients with aortic valve disease undergoing surgery. In a population of 2011 patients undergoing AVS, 
the presence of an enlarged LA preoperatively was associated with higher long-term all-cause and 
cardiovascular mortality, as well as with the combined event stroke and cardiovascular mortality.  
 
Beach and colleagues
8
 found that severe preoperative LA dilatation, expressed as nonindexed LA 
diameter, was predictive of a larger residual LA size and substantially reduced long-term survival after 
AVS in patients with aortic stenosis.  
 
To the best of our knowledge, this is the first study addressing the value of indexed LA diameter as a 
predictor of long-term results in this subset of patients who typically present an impaired diastolic LV 
function and chronically elevated LV filling pressures.  
 
Different LA measurements have been identified as predictors of stroke and death in the general 
population.
1,2,15
 LA size increases with persistently elevated LV filling pressure and has been correlated 
with the severity of aortic valve stenosis.
16-18
 Casaclang-Verzosa and colleagues
7
 demonstrated that 
nonindexed LA diameter was related to mortality in asymptomatic patients with severe AS. In our study, 
LA enlargement was significantly more prevalent among patients with aortic valve stenosis than those 
with regurgitation.  
 
LA enlargement also is a common echocardiographic finding in hypertensive patients.
19-21
 Cuspidi and 
colleagues
19
 related LA size and enlargement to LV mass and hypertrophy. Our findings are in line with 
those from other authors, and the group with LA enlargement presented a significantly higher rate of 
arterial hypertension.  
 
In both types of patients, the increase of LVend-diastolic pressure is associated with an increase in 
diastolic filling and a significant reduction of active and passive emptying contribution of left atrium to 
LV stroke volume.
22
  
 
In hypertensive patients, strokes have been associated with larger LA sizes.
21
 In 2013, Shin and 
colleagues
23
 suggested that LA enlargement influenced most patients in all subtypes of ischemic stroke 
but was most prevalent in the cardioembolic stroke subtype. Although in our series, indexed LA size 
increased the risk of stroke in 50.7% per 1-cm/m
2
 enlargement in univariable analysis, multivariate 
competing risks regression could not confirm that association. However, when analyzing the combined 
event cardiovascular death or stroke, indexed LA size proved to be an independent risk factor in the 
multivariate analysis. In our series, we found that 15.6% of the patients had a cardiovascular death or a 
stroke, among whom 31 had both events. There was a 67.3% increase in the risk of cardiovascular death 
or stroke per each centimeter per square meter of increment in indexed LA diameter.  
 
More than 73% of the patients in this series received a biological AV prosthesis. This proportion was 
significantly higher among patients with an enlarged LA. The rationale behind this finding is that the 
group with LA enlargement was significantly older and therefore more prone to benefit from a biological 
prosthesis. Of note, the multivariate analysis did not confirm any specific surgical procedure over the 
aortic valve (repair, bioprosthesis, or mechanical prosthesis) as an independent predictor for long-term 
survival.  
 
Despite a higher expected operative mortality as determined by both euroSCORE I and II, observed 
in-hospital mortality was not significantly higher in the group with enlarged LA. Our results demonstrate 
that an enlarged LA poses a significant risk of all-cause mortality in patients undergoing AVS. We found 
a 54.5% higher risk of all-cause mortality per 1-cm/m
2
 increment in indexed LA diameter. By using the 
definition of cardiovascular death as recommended by the American College of Cardiology,
13
 we found 
249 cardiovascular deaths in the whole series. Cardiovascular deaths accounted for 66.8% of late deaths 
in the group of LA enlargement, being significantly more frequent than in patients with normal LA 
dimensions. Moreover, indexed LA size increased the risk of cardiovascular death in more than 97.1% 
per 1-cm/m2 increment. This finding emphasizes the paramount importance of an enlarged LA in patients 
with aortic valve diseases who undergo an AVS. 
CONCLUSIONS 
Indexed LA measurements reflect the burden of elevated LV filling pressure in this critical subset of 
patients. Indexed LA diameters are strong predictors of long-term outcome of these patients; therefore, 
they may be useful to guide the best therapy for aortic valve diseases. These indexed measurements 
should become a routine laboratory measure in the preoperative evaluation of patients with aortic valve 
diseases (Video 1).  
 
 
 
VIDEO 1. The more relevant findings of the study are summarized. Video available at: http://www.jtcvs.org. 
Finally, future efforts should focus on assessing the postoperative change in indexed LA size and its 
potential value as a marker of the degree of relief of LV volume or pressure overload and therefore of the 
surgical result.  
Study Limitations  
This study presents the limitations inherent in any retrospective study. A total of 400 patients were 
excluded from the study because of the absence of echocardiographic data regarding LA dimension. Risk 
factors of excluded and included patients have been compared. There were no statistically significant 
differences between both groups (Table E9).  
  
Although we performed a thorough search across several databases, the cause of late death could not 
be determined in 43 patients. On the other hand, as described by Lauer and colleagues,
24
 the 
ascertainment of the cause of death may be susceptible to bias and misclassification.  
 
Although we controlled for several important covariables, because this was an observational study, 
residual confounding may account for at least part of the observed differences in outcome.  
 
Some studies have pointed out that LA volume is a more reliable estimator of LA size than LA 
diameter
9,25 
and may be a more accurate predictor of cardiovascular events.
26
 Nevertheless, indexed LA 
diameter is more readily available and more widely used in clinical practice. In addition, LA diameters, 
when indexed to BSA, account for the sex differences in LA size by variation in body size.
9,11,12
  
 
Finally, enlargement of the LA mainly represents the chronic effect of elevated LV filling pressures 
on the LA. However, this study did not analyze the prognostic role of diastolic parameters, such as the 
mitral septallateral e´ and E/e´ ratio.
9
 Further studies are warranted to compare the prognostic role of LA 
enlargement with other parameters of LV diastolic function, such as the mitral septal-lateral e´ and E/e´ 
ratio.  
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TABLE E1. Binary logistic regression model for in-hospital mortality 
Variable  HR 95% CI P value 
    
Indexed LA diameter (cm/m2)  1.061 0.686-1.642 .789 
Sex (female)  1.227 0.773-1.947 .386 
Age (y)  1.069 1.030-1.108 <.001 
Active endocarditis  1.432 0.467-4.392 .530 
Previous cardiac surgery  1.187 0.592-2.382 .629 
BSA (m2)  0.191 0.044-0.841 .029 
Chronic lung disease  1.125 0.805-1.572 .490 
Extracardiac arteriopathy  1.119 0.474 -2.642 .798 
Creatinine clearance (mL/min)  0.994 0.986-1.003 .184 
Mitral valve disease grade 2+  0.663 0.396-1.192 .170 
History of AF  1.012 0.664-1.321 .850 
History of stroke  1.031 0.747-1.425 .850 
LV dysfunction    .038 
Mild (45%-54%)  1.458 0.847-2.510 .174 
Moderate (30%-45%)  2.281 0.865-6.016 .095 
Severe (<30%)  8.990 1.421-56.864 .002 
Pulmonary hypertension    .012 
Moderate (31-55 mm Hg)  1.116 0.634-1.966 .704 
Severe (>55 mm Hg)  2.651 1.374-5.113 .004 
Concomitant mitral valve surgery  3.230 1.368-7.623 .007 
Concomitant CABG  1.512 0.731-3124 .265 
Concomitant surgery on thoracic aorta  1.025 0.553-1.902 .936 
Cardiopulmonary bypass time  1.005 1.002-1.009 .004 
Aortic crossclamp time  1.009 1.001-1.017 .034 
    
 
HR, Hazard ratio; CI, confidence interval; LA, left atrial; BSA, body surface 
area; AF, atrial fibrillation; LV, left ventricle; CABG, coronary artery bypass 
grafting. 
  
TABLE E2. Kaplan–Meier survival at 1, 3, 5, and 7 years for each panel of each figure, reporting 95% confidence limits in brackets 
Degree of LA enlargement  1y 3y 5y 7y 
 
Figure 1, A, Kaplan–Meier survival curves for all-cause mortality stratified according to indexed LA diameter. 
Overall  89.6% (88.2-90.9%) 82.2% (80.2-84%) 72.1% (69.4-74.7%) 59.5% (55.4-63.3%) 
Normal LA  94.6% (92.6-95.2%) 92% (90.3-93%) 91.6% (89.9-93%) 65.9% (60.5-70.8%) 
Mild LA enlargement  90% (84.6-93.6%) 81.6% (74.6-86.8%) 65.9% (56.1-74%) 56.6% (43.3-67.9%) 
Moderate LA enlargement  87.7% (82.9-91.2%) 79.4% (73.2-84.3%) 59.9% (51.2-67.6%) 50.9% (40.3-60.6%) 
Severe LA enlargement  83.5% (78.7-87.4%) 73.1% (67.1-78.3%) 60.7% (52.8-67.7%) 44.3% (34.6-53.4%) 
Figure 1, B, Kaplan–Meier curves for cardiovascular survival stratified according to indexed LA diameter. 
Overall  98.3% (97.6-98.8%) 95% (93.7-96.1%) 91% (88.9-92.8%) 85.9% (82.3-88.9%) 
Normal LA  99.7% (96-99.9%) 98.2% (96.9-98.9%) 97.6% (96-98.6%) 93.9% (89.4-96.5%) 
Mild LA enlargement  96% (92.5-99.9%) 92.3% (87.4-95.3%) 86.8% (79.4-91.7%) 83.3% (72.2-90.3%) 
Moderate LA enlargement  95.9% (91.6-98%) 88.9% (82.4-93.1%) 77.9% (67.9-85.2%) 70.1% (55.2-80.9%) 
Severe LA enlargement  96.1% (92.8-97.9%) 88.2% (82.7-92%) 77.4% (68.8-83.9%) 68.4% (57.1-77.3%) 
Figure 2, A, Survival free of stroke stratified according to indexed LA diameter. 
Overall  98.1% (97.3-98.7%) 95.8% (94.6-96.7%) 93% (91.2-94.4%) 88.9% (85.6-91.5%) 
Normal LA  98.5% (97.5-99%) 95.8% (94.2-97%) 94% (91.8-95.6%) 88.6% (83.8-92%) 
Mild LA enlargement  98.2% (95.2-99.3%) 97.5% (94.1-99%) 90.9% (83.4-95.1%) 90.9% (83.4-95.1%) 
Moderate LA enlargement  98.2% (94.4-99.4%) 97.3% (93-99%) 91.4% (82.7-95.9%) 91.4% (82.7-95.9%) 
Severe LA enlargement  96.4% (93.1-98.1%) 92.9% (88.4-95.7%) 91.3% (86.1-94.6%) 87.3% (78.7-92.6%) 
Figure 2, B, Survival free of the combined event, cardiovascular death or stroke, stratified according to indexed LA diameter. 
Overall  91.2% (89.8-92.4%) 86% (84.2-87.6%) 79.9% (77.5-82.2%) 72.5% (68.6-75.9%) 
Normal LA  93.3% (91.8-94.6%) 89.5% (87.4-91.2%) 87.2% (84.7-89.4%) 79% (73.7-83.3%) 
Mild LA enlargement  89.3% (84.7-92.6%) 85.2% (79.7-89.3%) 74.5% (66.3-81%) 74.5% (66.3-81%) 
Moderate LA enlargement  89.9% (84.5-93.5%) 83.2% (76.2-88.2%) 68% (57.7-76.2%) 61.2% (47.8-72.1%) 
Severe LA enlargement  84.2% (79.4-87.9%) 74.4% (68.3-79.4%) 64.5% (56.8-71.1%) 54.5% (44.8-63.2%) 
Figure 3, A, Kaplan–Meier curves for cardiovascular survival in patients with aortic valve stenosis (n = 1639) stratified according to 
indexed LA diameter. 
Overall  93.8% (92.5-94.9%) 89.7% (87.9-91.3%) 84.2% (81.5-86.6%) 78.9% (74.6-82.6%) 
Normal LA  95.9% (94.4-97%) 94% (92.1-95.5%) 93% (90.6-94.8%) 88.2% (82.5-92.2%) 
Mild LA enlargement  91% (86.1-94.2%) 86.7% (80.7-91%) 80.1% (71.9-86.1%) 76.1% (64.1-84.5%) 
Moderate LA enlargement  92.4% (86.7-95.7%) 86% (78.5-91%) 70.6% (58.6-79.8%) 66.5% (52.1-77.4%) 
Severe LA enlargement  88.7% (83.7-92.2%) 78.7% (72-84%) 66.8% (57.4-74.5%) 58.4% (46.9-57.6%) 
Figure 3, B, Kaplan–Meier curves for cardiovascular survival in patients with aortic valve regurgitation (n = 372) stratified 
according to indexed LA diameter. 
Overall  86.9% (82.8-90%) 84.5% (79.9-88.1%) 82.3% (77.1-86.4%) 76.8% (69-82.8%) 
Normal LA  91.1% (86.8-94%) 88.4% (83.2-92%) 87.1% (81.2-91.2%) 83.5% (75.4-89.2%) 
Mild LA enlargement  80.4% (61.5-90.7%) 80.4% (61.5-90.7%) 72.4% (47.4-86.9%) 72.4% (47.4-86.9%) 
Moderate LA enlargement  84% (62.7-93.7%) 84% (62.7-93.7%) 78% (54.1-90.5%) 52% (9.7-83.3%) 
Severe LA enlargement  68.6% (52.1-80.5%) 64.1% (46.1-77.4%) 64.1% (46.1-77.4%) 53.4% (28.5-73%) 
     
 
LA, Left atrial. 
 
 
  
TABLE E3. Multivariate Cox proportional hazards model: Survival all-cause mortality 
Variable  HR 95% CI P value 
    
Indexed LA diameter (cm/m2)  1.545 1.252-1.906 <.001 
Sex (female)  1.168 0.914-1.492 .214 
Age (y) 1.041 1.024-1.058 <.001 
Aortic valve regurgitation (reference aortic valve stenosis) 0.989 0.707-1.384 .950 
Active endocarditis  2.606 1.580-4.299 <.001 
Previous cardiac surgery  1.485 1.057-2.088 .023 
BSA (m2)  1.662 0.845-3.267 .141 
Chronic lung disease  1.125 0.805-1.572 .490 
Extracardiac arteriopathy  0.813 0.523-1.265 .359 
Creatinine clearance (mL/min)  1 0.996-1.003 .853 
Mitral valve disease grade 2+  0.859 0.667-1.108 .242 
History of AF  1.032 0.747-1.425 .850 
History of stroke  1.232 0.893-1.682 .09 
Coronary artery disease  1.185 0.735-2.259 .238 
LV dysfunction    <.001 
Mild (45%-54%)  1.551 1.208-1.991 .001 
Moderate (30%-45%)  1.606 0.979-2.633 .06 
Severe (<30%)  9.237 4.184-20.392 <.001 
Pulmonary hypertension    .003 
Moderate (31-55 mm Hg)  0.920 0.717-1.181 .513 
Severe (>55 mm Hg)  1.690 1.203-2.374 .002 
Type of AVS (reference valve repair)    .290 
Mechanical  0.968 0.291-3.227 .958 
Biological  0.738 0.224-2.433 .738 
Concomitant mitral valve surgery  1.751 1.244-2.464 .001 
Concomitant CABG  1.102 0.864-1.406 .432 
Concomitant surgery on thoracic aorta  0.896 0.605-1.327 .584 
Arterial hypertension  1.330 1.058-1.672 .15 
Dyslipidemia  0.897 0.732-1.099 .292 
Diabetes mellitus  1.160 0.933-1.442 .182 
    
 
HR, Hazard ratio; CI, confidence interval; LA, left atrial; BSA, body surface area; AF, atrial fibrillation; LV, left ventricle; AVS, 
aortic valve surgery; CABG, coronary artery bypass grafting. 
  
TABLE E4. Cox proportional hazards model: Survival cardiovascular mortality 
Variable  HR 95% CI P value 
    
Indexed LA diameter (cm/m2)  1.971 1.541-2.520 <.001 
Sex (female)  0.926 0.663-1.294 .654 
Age (y)  1.055 1.031-1.079 <.001 
Aortic valve regurgitation (reference aortic valve stenosis) 1.594 1.083-2.345 .018 
Active endocarditis  3.461 1.927-6.218 <.001 
Previous cardiac surgery  0.999 0.621-1.607 .997 
BSA (m2)  0.675 0.269-1.695 .403 
Chronic lung disease  1.210 0.781-1.874 .393 
Extracardiac arteriopathy  0.826 0.465-1.467 .515 
Creatinine clearance (mL/min)  0.996 0.990-1.002 .157 
Mitral valve disease grade 2+  0.876 0.628-1.222 .436 
History of AF  0.848 0.556-1.293 .444 
History of stroke  1.287 0.628-1.982 .12 
Coronary artery disease  1.593 0.732-2.679 .273 
LV dysfunction    <.001 
Mild (45%-54%)  1.578 1.134-2.196 .007 
Moderate (30%-45%) 1.903 1.005-3.605 .048 
Severe (<30%)  16.319 6.270-42.472 <.001 
Pulmonary hypertension    .001 
Moderate (31-55 mm Hg)  0.754 0.532-1.071 .115 
Severe (>55 mm Hg)  1.805 1.190-2.739 .005 
Type of AVS (reference valve repair)    .755 
Mechanical  0.569 0.127-2.558 .462 
Biological  0.614 0.140-2.700 .519 
Concomitant mitral valve surgery  1.522 0.978-2.368 .063 
Concomitant CABG  1.080 0.770-1.515 .655 
Concomitant surgery on thoracic aorta  1.875 0.593-1.290 .499 
Arterial hypertension  1.331 0.979-1.810 .068 
Dyslipidemia  0.857 0.651-1.129 .272 
Diabetes mellitus  1.220 0.910-1.636 .183 
    
 
HR, Hazard ratio; CI, confidence interval; LA, left atrial; BSA, body surface area; AF, atrial fibrillation; LV, left ventricle; AVS, 
aortic valve surgery; CABG, coronary artery bypass grafting. 
  
TABLE E5. Fine-Gray proportional hazard regression for incidence of stroke accounting for competing events (death) 
Variable  HR 95% CI P value 
    
Indexed LA diameter (cm/m2)  1.237 0.724-2.114 .68 
Sex (female)  0.668 0.562-1.424 .23 
Age (y)  0.996 0.969-1.025 .81 
Aortic valve regurgitation (reference aortic valve stenosis) 1.867 1.006-3.466 .048 
Active endocarditis  1.290 0.389-4.275 .68 
Previous cardiac surgery  0.454 1.154-1.334 .15 
BSA (m2)  0.885 0.220-3.554 .86 
Chronic lung disease  0.601 0.234-1.542 .29 
Extracardiac arteriopathy  0.789 0.315-1.972 .61 
Creatinine clearance (mL/min)  0.994 0.990-0.998 .007 
Mitral valve disease grade 2+  0.877 0.495-1.553 .65 
History of AF  1.206 0.611-2.381 .59 
History of stroke  2.501 0.320-19.54 .38 
Coronary artery disease  2.148 1.069-4.317 .032 
LV dysfunction    .15 
Mild (45%-54%)  1.639 0.942-2.850 .08 
Moderate (30%-45%)  0.768 0.385-2.716 .81 
Severe (<30%)  4.371 0.829-26.006 .12 
Pulmonary hypertension    .43 
Moderate (31-55 mm Hg)  0.736 0.572-1.196 .64 
Severe (>55 mm Hg)  1.639 0.203-3.716 .25 
Type of AVS (reference valve repair)    .830 
Mechanical  1.102 0.901-1.534 .49 
Biological  0.497 0.717-2.14 .37 
Concomitant mitral valve surgery  1.641 0.735-3.663 .23 
Concomitant CABG  1.611 0.952-2.727 .076 
Concomitant surgery on thoracic aorta  1.318 0.556-3.123 .53 
Arterial hypertension  1.439 0.875-2.368 .15 
Dyslipidemia  0.704 0.235-1.959 .50 
Diabetes mellitus  1.231 0.759-1.959 .40 
    
 
HR, Hazard ratio; CI, confidence interval; LA, left atrial; BSA, body surface area; AF, atrial fibrillation; LV, left ventricle; AVS, 
aortic valve surgery; CABG, coronary artery bypass grafting. 
  
TABLE E6. Multivariate Cox proportional hazards model: Freedom from combined event (cardiovascular death or stroke) 
Variable  HR 95% CI P value 
    
Indexed LA diameter (cm/m2)  1.673 1.321-2.119 <.001 
Sex (female)  0.966 0.716-1.302 .819 
Age (y)  1.038 1.018-1.058 .001 
Aortic valve regurgitation (reference aortic valve stenosis) 1.461 1.027-2.079 .035 
Active endocarditis  3.414 2.024-5.756 <.001 
Previous cardiac surgery  1.042 0.683-1.592 .848 
BSA (m2)  0.513 0.226-1.165 .111 
Chronic lung disease  0.141 0.763-1.706 .520 
Extracardiac arteriopathy  0.826 0.493-1.385 .469 
Creatinine clearance (mL/min)  0.998 0.993-1.002 .368 
Mitral valve disease grade 2+  0.812 0.579-1.138 .226 
History of AF  0.809 0.521-1.258 .347 
History of stroke  1.329 1.151-2.373 .031 
Coronary artery disease  1.461 0.732-1.581 .19 
LV dysfunction    <.001 
Mild (45%-54%)  1.503 1.112-2.033 .008 
Moderate (30%-45%)  1.498 0.796-2.819 .210 
Severe (<30%)  13.229 5.538-31.600 <.001 
Pulmonary hypertension    .01 
Moderate (31-55 mm Hg)  0.759 0.554-1.039 .086 
Severe (>55 mm Hg)  1.744 1.185-2.567 .005 
Type of AVS (reference valve repair)    .722 
Mechanical  1.906 0.717-3.596 .421 
Biological  0.772 0.172-2.084 .462 
Concomitant mitral valve surgery  1.754 1.134-2.713 .012 
Concomitant CABG  1.138 0.815-1.587 .448 
Concomitant surgery on thoracic aorta  0.868 0.530-1.421 .573 
Arterial hypertension  1.297 0.958-1.755 .093 
Dyslipidemia  0.992 0.755-1.303 .954 
Diabetes mellitus  1.175 0.880-2.713 .273 
    
 
HR, Hazard ratio; CI, confidence interval; LA, left atrial; BSA, body surface area; AF, atrial fibrillation; LV, left ventricle; AVS, 
aortic valve surgery; CABG, coronary artery bypass grafting. 
 
  
TABLE E7. Cox proportional hazards model: Survival cardiovascular mortality in the subgroup of patients with aortic valve 
stenosis (n = 1639) 
Variable  HR 95% CI P value 
    
Indexed LA diameter (cm/m2)  1.947 1.454-2.607 <.001 
Sex (female)  0.677 0.463-0.990 .044 
Age (y)  1.052 1.024-1.082 <.001 
Active endocarditis  6.027 0.823-44.139 .077 
Previous cardiac surgery  0.914 0.526-1.588 .749 
BSA (m2)  0.388 0.135-1.114 .079 
Chronic lung disease  1.147 0.682-1.928 .605 
Extracardiac arteriopathy  1.572 0.933-2.650 .089 
Creatinine clearance (mL/min)  0.428 0.992-1.003 .428 
Mitral valve disease grade 2+  1.006 0.698-1.449 .976 
History of AF  1.053 0.669-1.659 .822 
History of stroke  1.256 0.625-1.922 .211 
Coronary artery disease  1.009 0.695-1.465 .961 
LV dysfunction    <.001 
Mild (45%-54%)  1.419 0.957-2.103 .082 
Moderate (30%-45%)  1.702 0.840-3.447 .14 
Severe (<30%)  14.264 5.354-38.000 <.001 
Pulmonary hypertension    .017 
Moderate (31-55 mm Hg)  0.979 0.665-1.443 .915 
Severe (>55 mm Hg)  1.981 1.209-3.246 .007 
Type of AVS (reference valve repair)    .994 
Mechanical  0.719 0.323-4.287 .911 
Biological  0.811 0.143-1.998 .877 
Concomitant mitral valve surgery  1.088 0.608-1.949 .776 
Concomitant CABG  1.091 0.799-1.815 .961 
Concomitant surgery on thoracic aorta  1.881 0.598-1.791 .974 
Arterial hypertension  1.351 0.946-1.931 .098 
Dyslipidemia  0.754 0.550-1.035 .081 
Diabetes mellitus  1.320 0.952-1.832 .089 
    
 
HR, Hazard ratio; CI, confidence interval; LA, left atrial; BSA, body surface area; AF, atrial fibrillation; LV, left ventricle; AVS, 
aortic valve surgery; CABG, coronary artery bypass grafting. 
  
TABLE E8. Cox proportional hazards model: Survival cardiovascular mortality in the subgroup of patients with aortic valve 
regurgitation (n = 372) 
Variable  HR 95% CI P value 
    
Indexed LA diameter (cm/m2)  2.101 1.167-3.782 .013 
Sex (female)  0.455 0.210-0.983 .045 
Age (y)  1.052 1.008-1.098 .019 
Active endocarditis  5.034 1.231-21.989 .006 
Previous cardiac surgery  1.342 0.490-3.675 .566 
BSA (m2)  5.675 0.669-48.142 .111 
Chronic lung disease  0.914 0.377-2.218 .843 
Extracardiac arteriopathy  1.020 0.222-4.678 .98 
Creatinine clearance (mL/min)  0.999 0.990-1.008 .782 
Mitral valve disease grade 2+ 2.116 0.943-4.747 .069 
History of AF  2.469 0.730-8.352 .146 
History of stroke  1.331 0.321-1.999 .331 
Coronary artery disease  1.018 0.420-2.468 .968 
LV dysfunction    .605 
Mild (45%-54%)  17.025 0-NA .970 
Moderate (30%-45%)  24.124 0-NA .966 
Severe (<30%)  37.206 0-NA .961 
Pulmonary hypertension    .024 
Moderate (31-55 mm Hg)  0.262 0.299-1.388 .915 
Severe (>55 mm Hg)  0.007 0.100-0.699 .007 
Type of AVS (reference valve repair)    .991 
Mechanical  1.076 0.211-5.481 .929 
Biological  1.023 0.219-4.784 .977 
Concomitant mitral valve surgery  0.333 0.148-0.750 .008 
Concomitant CABG  1.077 0.739-2.338 .861 
Concomitant surgery on thoracic aorta  1.504 0.760-2.977 .241 
Arterial hypertension  0.871 0.465-1.632 .667 
Dyslipidemia  1.038 0.582-1.851 .901 
Diabetes mellitus  0.856 0.401-1.829 .689 
    
 
HR, Hazard ratio; CI, confidence interval; LA, left atrial; BSA, body surface area; AF, atrial fibrillation; LV, left ventricle; NA, not 
available; AVS, aortic valve surgery; CABG, coronary artery bypass grafting. 
  
TABLE E9. Demographics, clinical risk factors, and surgical data of the excluded (n = 400) and included (n = 2011) populations 
Characteristic 
Excluded patients  
(n = 400) 
Included patients 
(n = 2011) 
P value 
    
Sex (male)  238 (59.5%) 1180 (58.7%) .76 
Age, y, mean (SD)  69.8 ± 11.1 70.9 ± 10.8 .064 
BMI, mean (SD)  29.1 ± 4.6 28.7 V 4.4 .099 
BSA, m2, mean (SD)  1.8 ± 0.1 1.8 ± 0.2 .999 
Preoperative anticoagulation with VKAs  40 (10%) 236 (11.7%) .319 
Arterial hypertension  281 (70.2%) 1367 (68%) .371 
Dyslipidemia  210 (52.5%) 1101 (54.7%) .409 
Diabetes mellitus  100 (25%) 496 (24.7%) .887 
Creatinine clearance, mL/min, mean (SD)  63.5 ± 25.9 64.1 ± 27.4 .686 
Chronic lung disease  42 (10.5%) 174 (8.7%) .237 
Extracardiac arteriopathy  27 (6.7%) 127 (6.3%) .745 
History of atrial fibrillation  38 (9.5%) 236 (11.7%) .198 
History of stroke or TIA  11 (2.7%) 90 (4.5%) .116 
History of cardiac surgery  40 (10%) 181 (9%) .527 
Coronary artery disease  92 (23%) 445 (22.1%) .751 
Active endocarditis  12 (3%) 59 (2.9%) .943 
Predominant aortic valve stenosis  316 (79%) 1639 (81.5%) .273 
Predominant aortic valve regurgitation  84 (21%) 372 (18.5%)  
Moderate or severe mitral valve disease  96 (24%) 444 (22.1%) .4 
LV dysfunction    
Normal LVEF (>55%)  307 (76.8%) 1626 (80.9%) .28 
Mild LV dysfunction (45%-54%)  76 (19%) 315 (15.7%)  
Moderate LV dysfunction (30%-45%)  14 (3.5%) 61 (3%)  
Severe LV dysfunction (<30%)  3 (0.7%) 9 (0.4%)  
Pulmonary hypertension    
Normal PAP  293 (73.2%) 1519 (75.5%)  
Moderate (31-55 mm Hg)  68 (17%) 359 (17.9%) .083 
Severe (>55 mm Hg)  39 (9.8%) 133 (6.6%)  
Logistic euroSCORE I, mean (SD)  8.5 ± 7.5 8.4 ± 7.4 .805 
Logistic euroSCORE II, mean (SD)  4.4 ± 4.3 4.3 ± 4.5 .682 
Type of AVS    
Valve repair  7 (1.8%) 53 (2.6%)  
Biological  312 (78%) 1481 (73.6%) .162 
Mechanical  81 (20.2%) 477 (23.7%)  
Emergency surgery (<24 h)  14 (3.5%) 45 (2.2%) .135 
Concomitant procedure  165 (41.4%) 852 (42.4%) .41 
Concomitant mitral valve surgery  45 (11.2%) 191 (9.5%) .324 
Concomitant CABG  79 (19.8%) 385 (19.1%) .779 
Concomitant surgery on thoracic aorta  47 (11.7%) 305 (15.2%) .191 
    
 
SD, Standard deviation; BMI, body mass index; BSA, body surface area; VKA, vitamin K antagonist; TIA, transient ischemic 
attack; LV, left ventricle; LVEF, left ventricular ejection fraction; PAP, pulmonary artery pressure; euroSCORE, European System 
for Cardiac Operative Risk Evaluation; AVS, aortic valve surgery; CABG, coronary artery bypass grafting. 
 
 
 
